Objective: Arteriovenous fistulas created in patients with chronic kidney disease often lose patency and fail to become usable. This prospective trial evaluated the efficacy of vonapanitase, a recombinant human elastase, in promoting radiocephalic fistula patency and use for hemodialysis.
Permanent vascular access was the major obstacle to chronic hemodialysis until the development of the radiocephalic fistula, described by Brescia and Cimino in 1966. 1 The arteriovenous fistula remains a lifeline for hemodialysis patients and is associated with a survival benefit over other forms of vascular access. 2, 3 Despite this, in 2016, 80% of patients started hemodialysis using a catheter. 4 Within 1 year of surgical creation, 40% to 70% of fistulas thrombose or require a corrective procedure, 20% to 30% are abandoned, [5] [6] [7] [8] [9] and 30% to 60% fail to become usable for hemodialysis. [7] [8] [9] [10] [11] Radiocephalic fistulas are at greater risk of failure than more proximal fistulas, [6] [7] [8] 10, 12, 13 even though they are the optimal form of vascular access that maximizes the number of future possibilities for access placement.
After creation of a fistula, there is a rapid increase in blood flow resulting from the anastomosis of a highpressure artery to a low-pressure, low-resistance vein. This increase in flow leads to vascular remodeling with dilation and medial thickening. 15, 16 In this manner, the fistula matures and can be cannulated for hemodialysis. Unfortunately, many fistulas fail to mature successfully because of impaired outward vascular remodeling. 17 In addition, vascular injury at the time of fistula creation and subsequent hemodynamic changes, including turbulent blood flow, can cause quiescent cells in the middle (medial) and outer (adventitial) vessel wall layers to proliferate and migrate toward the inner (intimal) layer and to secrete extracellular matrix. 17 The resulting intimal hyperplasia inhibits maturation and causes luminal stenosis or thrombosis in up to 50% of fistulas and is the primary cause of corrective procedures, fistula nonuse, and abandonment. 18 Vonapanitase (formerly PRT-201) is a recombinant human chymotrypsin-like elastase family member 1 (CELA1) that cleaves the peptide bonds in the protein elastin. 19 When vonapanitase is applied locally during fistula creation, it is rapidly absorbed into the outermost vessel layer, where it fragments elastin fibers. 20, 21 Elastin fragmentation by endogenous elastases (matrix metalloproteinases) is an early and essential component of outward vascular remodeling in animal fistula models. 22 Elastin fragments (peptides) created by CELA1 have chemotactic properties that may inhibit cell migration to the intima. 22, 23 Previous phase 1 and phase 2 clinical trials have shown that vonapanitase 0.03 mg, a dose that partially fragments elastin in the forearm cephalic vein, may increase fistula and arteriovenous graft blood flow 24, 25 and improve fistula maturation, patency, and use for hemodialysis. 26, 27 This larger prospective trial was conducted to confirm whether vonapanitase improves outcomes in patients undergoing radiocephalic fistula creation.
METHODS
Trial population. Patients were eligible for enrollment if they had advanced chronic kidney disease and were on hemodialysis or planning to initiate hemodialysis and were being considered for radiocephalic fistula creation. Exclusion criteria included life expectancy <6 months, active malignant disease, and previous treatment with vonapanitase. There was no other selection process at the sites.
Trial design. PATENCY-1 was a randomized, doubleblind, placebo-controlled trial performed at 31 clinical sites. Intraoperatively, after the surgeon confirmed that a radiocephalic fistula would be created, patients were randomized 2:1 to vonapanitase 0.03 mg or placebo using either an interactive voice or web response system (created by Bracket, Langhorne, Pa). The site-specific randomization was stratified by hemodialysis status.
Drug vials contained a lyophilized cake that was reconstituted with 3 mL of sterile water to yield a clear, nonviscous liquid. After anastomosis creation and removal of vascular clamps, the surgeon lavaged the surgical site to remove blood from the field and then administered 1 drop, 1 drop, and 4 drops of the study drug to the inflow artery, anastomosis, and outflow vein, respectively, every 20 seconds for 10 minutes. The surgeon then irrigated the surgical site with saline for 1 minute. Treatment was interrupted if any active bleeding was noted because vonapanitase is inactivated by blood. 28 After cessation of bleeding, administration of the study drug recommenced. Topical procaine, bicarbonate solution, vancomycin, and ultrasound acoustic gel were not allowed in the surgical field as they are known to inhibit vonapanitase. Safety assessments were performed immediately postoperatively and at 2 and 6 weeks and 3, 6, 9, and 12 months. Serum chemistry parameters and a complete blood cell count were measured at screening and week 2. Serum antivonapanitase antibodies were measured at screening, week 2, and week 6. A duplex Doppler ultrasound examination of the fistula was performed at 6 weeks and 3 months to assess outflow vein diameter, measured at three predetermined locations in the forearm, and blood flow rate, measured 5 cm above the fistula anastomosis.
Trial oversight. PATENCY-1 was sponsored by Proteon Therapeutics, Inc, and performed in accordance with the principles of the Declaration of Helsinki. The Institutional Review Board of each participating clinical site approved the trial protocol and informed consent document. The trial was monitored by SynteractHCR (Carlsbad, Calif), and statistical analysis was performed by PROMETRIKA, LLC (Cambridge, Mass). An independent data monitoring committee reviewed blinded safety data after 150 patients completed the week 6 study visits. The ultrasonography core lab was VasCare (Boston, Mass). Serious adverse event monitoring was done by Premier Research (Philadelphia, Pa). Antivonapanitase antibody testing was conducted by PPD (Richmond, Va). The protocol is available in Appendix 1 (online only). End points and assessments. The primary end point was primary patency, defined as the time from fistula creation until thrombosis or a procedure to restore or to maintain patency. 29 The secondary end point was secondary patency, defined as the time from fistula creation until fistula abandonment. 29 Abandonment was defined as a fistula that can no longer be used for hemodialysis as it may be unable to provide adequate blood flow or it is deemed unsafe for the patient and the associated problem cannot be corrected by an intervention, including medical, surgical, or radiologic intervention, or rest. Tertiary end points included unassisted fistula use for hemodialysis, unassisted maturation by ultrasound, and rate of procedures to restore or to maintain fistula patency. The primary analysis of efficacy end points was based on the full analysis set of patients (intent to treat) with the exception of the use for hemodialysis end point. Use was defined as the ability of the fistula to be cannulated with two needles for a minimum of 90 days. If hemodialysis had not been initiated at least 90 days before the last visit, then use could be defined as cannulation with two needles for a minimum of 30 days and in use at the patient's last visit.
ARTICLE HIGHLIGHTS
In the remaining patients, nonuse was defined as fistula abandonment before use or <90 days of use. Those patients not defined as having use or nonuse (eg, never initiated hemodialysis) were considered indeterminate and excluded from the use for hemodialysis analysis. Fistula maturation was defined as an average outflow vein lumen diameter $4 mm and blood flow volume rate $500 mL/min by ultrasound. 30 Fistulas with missing ultrasound data were considered not mature. Unassisted meant that an outcome occurred without a prior procedure to restore or to maintain patency (thrombectomy, thrombolysis, balloon angioplasty, surgical patch angioplasty, or stent placement). Angiography, ligation or embolization of collateral vessels, and superficialization of the vein were not considered procedures to restore or to maintain patency but were included in an overall procedure rate. Procedure rates were calculated by dividing the number of days with procedures by the duration of follow-up for each patient. All adverse events were recorded from fistula creation until 6 weeks, and adverse events related to the fistula limb were recorded until 12 months.
Statistical analysis. A sample size of 300 was estimated to provide 96% power for an increase in median primary patency from 5 to 10 months (hazard ratio [HR], 0.50) and 97% power for an increase in secondary patency from 65% to 85% (HR, 0.38) at P < .05. A 10% dropout rate was assumed in these calculations.
Statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC). Baseline characteristics were compared using c 2 test, Fisher exact test, or t-test as appropriate. Primary and secondary patency and the components of primary patency (thrombosis-free survival and procedure-free survival) were estimated by Kaplan-Meier lifetest methods, and the survival curves were compared with a log-rank test. The analyses of primary and secondary patency were repeated for subsets based on hemodialysis status at randomization. HRs were estimated using a Cox proportional hazards model with treatment as a covariate. A Cox proportional hazards model including treatment and hemodialysis status was also used to assess the impact of baseline covariates on time to loss of primary and secondary patency. Covariates included study site; age categories (<65 years vs $65 years); sex; ethnicity (Hispanic vs non-Hispanic); race (white vs other); presence or absence of baseline diabetes, hypertension, hypercholesterolemia, congestive heart disease, ischemic heart disease, peripheral artery disease, and cerebrovascular disease; past or present catheter on same side as the study fistula; location of the fistula (wrist or snuffbox vs forearm); vein diameter ($ median, < median); artery diameter ($ median, < median); exposed vein length ($ median, < median); arteriotomy length; mode of anesthesia delivery (general, nerve block, or local); fluid or mechanical dilation; and use of perioperative medications (heparinized saline, papaverine, lidocaine, or intravenous heparin).
Fistula use for hemodialysis and fistula maturation were tested using c 2 tests. A logistic regression model including treatment and hemodialysis status was performed to identify and to adjust for any baseline covariates (described before) potentially associated with arteriovenous fistula use for hemodialysis. Outflow vein lumen diameter and blood flow volume rate were compared using t-tests. Primary and secondary patency and use for hemodialysis were also analyzed in a prespecified efficacy analysis set that excluded patients with primary or secondary patency loss by the week 2 visit under the assumption that these events represented technical failure of the surgery that could not be modified by the study treatments. The efficacy population also excluded patients who terminated early and had no information beyond the week 2 visit. To control the overall type I error rate at the two-sided .05 level, a hierarchical testing procedure was implemented. The order of end points in the hierarchy was primary patency, secondary patency, and unassisted arteriovenous fistula use for hemodialysis. If superiority was not demonstrated for the primary end point, the statistical evaluation of subsequent end points was viewed as descriptive.
RESULTS

Patients
From July 2014 through October 2015, there were 349 patients who were consented and 36 patients who were excluded on the basis of inclusion or exclusion criteria; these included 26 not having a radiocephalic fistula, 6 with inability to comply with protocol, 1 with confounding medical condition, 1 with lifeexpectancy <6 months, 1 with malignant disease, and 1 unable to obtain informed consent. Enrollment by site can be found in Appendix 2 (online only). Randomization occurred in 313 individuals (Fig 1) in a 2:1 manner, with 210 in the vonapanitase group and 103 in the placebo group. One patient in each group was randomized but not treated because of either inability to create a radiocephalic fistula or withdrawn consent. At randomization, 45% and 42% in the vonapanitase and placebo groups were receiving hemodialysis (Table) . An additional 54 (26%) patients in the vonapanitase group and 25 (24%) in the placebo group initiated hemodialysis during the follow-up period. The Table shows the baseline characteristics. There were no statistically significant differences between groups. Average duration of administration of the study drug was 10.1 minutes, and average volume administered was 2.50 mL. In 97% of cases, the study drug was administered per protocol. In three cases, the study drug was administered in <10 minutes; in five cases, it was administered in >10 minutes; and in 1 case, less than the complete volume was administered.
Outcomes
Primary end point. The median time to loss of primary patency was 214 days for vonapanitase and 171 days for placebo. The Kaplan-Meier estimates of primary patency (Fig 2, A) at 12 months were 42% (95% confidence interval [CI], 35-49) for vonapanitase and 31% (95% CI, 21-42) for placebo (P ¼ .25). The risk of primary patency loss was lower by 17% (HR, 0.83; 95% CI, 0.61-1.14) for vonapanitase. The cause of primary patency loss was a procedure to maintain patency in approximately twothirds and thrombosis in approximately one-third of cases. The Kaplan-Meier estimates of thrombosis-free fistula survival at 12 months were 78% (95% CI, 73-84) for vonapanitase and 70% (95% CI, 61-80) for placebo (P ¼.16). The risk of fistula thrombosis was 29% lower (HR, 0.71; 95% CI, 0.44-1.15) with vonapanitase. The Kaplan-Meier estimates of procedure-free fistula survival at 12 months were 47% (95% CI, 40-55) for vonapanitase and 38% (95% CI, 26-50) for placebo (P ¼ .38). The risk of fistula procedures was 14% lower (HR, 0.86; 95% CI, 0.60-1.21) for vonapanitase. Results for the primary patency end point were similar regardless of hemodialysis status. There was no significant treatment by clinical site interaction present. Use of local anesthesia was associated with increased risk of primary patency loss and use of papaverine was associated with a decreased risk of primary patency loss in a Cox model. Adjusting for these factors did not significantly change the magnitude of the vonapanitase treatment effect.
Secondary end point. The Kaplan-Meier estimates of secondary patency (Fig 2, B) at 12 months were 74% (95% CI, 68-80) for vonapanitase and 61% (95% CI, 51-71) for placebo (P ¼ .048). The risk of secondary patency loss was 34% lower (HR, 0.66; 95% CI, 0.43-1.00) for vonapanitase. Results for the secondary patency end point were similar regardless of hemodialysis status. General anesthesia and female sex were associated with increased risk of secondary patency loss. Adjusting for these factors did not significantly change the magnitude of the vonapanitase treatment effect.
Tertiary end points. The incidences of unassisted fistula use (Fig 3) , meaning without a prior procedure to restore or to maintain patency, were 39% (62/158) for vonapanitase and 25% (18/72) for placebo (P ¼ .035). The incidences of unassisted or assisted fistula use (Fig 3) were 64% (101/158) for vonapanitase and 44% (32/72) for placebo (P ¼ .006). These analyses excluded patients (vonapanitase, 52; placebo, 31) with indeterminate use because of not initiating hemodialysis or lacking sufficient follow-up to determine use. Prehemodialysis patients whose fistulas were abandoned before use were categorized as nonuse in this analysis.
In patients receiving hemodialysis at randomization, the incidences of unassisted or assisted use were 65% (57/88) for vonapanitase and 51% (19/37) for placebo (P ¼ .161). At 90 days after fistula creation, 38% (33/88) of vonapanitase and 19% (7/37) of placebo patients (P ¼ .042) were using the fistula for hemodialysis. In those with use, the times to initial cannulations were 104 6 62 (median, 81) days for vonapanitase and 119 6 67 (median, 114) days for placebo (P ¼ .381).
For patients who were prehemodialysis patients at randomization, the incidences of unassisted or assisted use were 63% (44/70) for vonapanitase and 37% (13/35) for placebo (P ¼ .013). In the subset of these patients who had their fistula created at least 6 weeks before the initiation of hemodialysis, 65% (32/49) of vonapanitase and 37% (7/19) of placebo patients initiated hemodialysis through the study fistula (P ¼ .033). In a logistic regression model, general anesthesia and female sex were associated with increased risk of fistula nonuse. Adjusting for these factors did not significantly change the magnitude of the vonapanitase treatment effect.
The incidences of unassisted fistula maturation by ultrasound criteria were 63% for vonapanitase and 53% for placebo (P ¼ .109). The incidences of unassisted or assisted fistula maturation were 66% for vonapanitase and 58% for placebo (P ¼ .170). The percentages of patients undergoing invasive procedures on the study fistula were similar between the two treatment groups, and the reasons for referrals for the interventions were also similar (Appendix 3, online only). There were 72 angioplasty procedures performed in 39 (38%) placebo patients, and 148 were performed in 77 (37%) vonapanitase patients. The locations of the angioplasties were the inflow artery, juxta-anastomotic segment, and outflow vein in 97% of cases, with the remaining 3% at a more proximal location, such as the cephalic arch and central veins (Appendix 3, online only). The rates of invasive procedures (procedure days per patient/year) on the study fistula were 1.5 6 2.1 for vonapanitase and 2.1 6 3.7 for placebo (P ¼ .149), and the rates of procedures to restore or to maintain patency were 1.1 6 1.8 for vonapanitase and 1.5 6 3.5 for placebo (P ¼ .479).
In those with patent fistulas, average outflow vein lumen diameters were similar at week 6 (vonapanitase, 5.3 6 1.1 mm; placebo, 5.3 6 1.1 mm; P ¼ .713) and month 3 (vonapanitase, 5.8 6 1.1 mm; placebo, 5.8 6 1.1 mm; P ¼ .827). Outflow vein blood flow volume rates were similar at week 6 (vonapanitase, 694 6 375 mL/min; placebo, 649 6 347 mL/min; P ¼ .511) and increased for vonapanitase at month 3 (vonapanitase, 798 6 391 mL/min; placebo, 668 6 356 mL/min; P ¼ .021).
Efficacy analysis set. Results for primary and secondary patency and use for hemodialysis were also assessed in the prespecified efficacy analysis set, which was designed to exclude early technical failures. This analysis excluded 29 patients, 19 (9%) vonapanitase and 10 (10%) placebo, who had primary or secondary patency loss (n ¼ 25) or early termination by the week 2 visit (n ¼ 4). The Kaplan-Meier estimates of primary patency at 12 months were 46% (95% CI, 38-53) for vonapanitase and 34% (95% CI, 22-45) for placebo (P ¼ .187); for secondary patency, they were 80% (95% CI, 74-86) for vonapanitase and 64% (95%, CI 53-74) for placebo (P ¼ .007). Unassisted or assisted use for hemodialysis was 71% for vonapanitase and 48% for placebo (P ¼ .001), and unassisted use was 44% for vonapanitase and 28% for placebo (P ¼ .026).
Safety
The incidences of adverse events were similar between groups. The most common adverse events (reported by $5.0% of patients in either group) were vascular stenosis (vonapanitase, 38.3%; placebo, 40.2%), fistula thrombosis (vonapanitase, 19.6%; placebo, 26.5%), hypoesthesia (vonapanitase, 5.3%; placebo, 4.9%), and procedural pain (vonapanitase, 4.8%; placebo, 5.9%). Fistula aneurysms were reported in one (1%) placebo patient and two (1%) vonapanitase patients. Seven (3.3%) vonapanitase patients and four (3.9%) placebo patients died during the study, with all deaths considered unrelated to the study drug. There were no meaningful changes 
DISCUSSION
In this PATENCY-1 trial, the topical application of vonapanitase at the time of fistula creation did not significantly improve primary patency. Whereas vonapanitase did not meet its primary end point, there were several clinically meaningful indicators that vonapanitase may be an effective therapy in fistula creation. Importantly, vonapanitase was associated with increases in secondary patency and use of the fistula for hemodialysis.
Participants in the placebo group had primary patency of 31% at 12 months, which is consistent with recently reported data for radiocephalic fistulas. [6] [7] [8] 10, 12, 13 Frequent early procedures, particularly balloon angioplasty, may have negatively affected the end point assessment. Clinicians are under significant pressure to establish a functioning fistula and to avoid catheter use. Loss of primary patency was due to the occurrence of procedures to restore or to maintain patency in two-thirds of cases and thrombosis in one-third of cases. Procedurefree survival was not different between groups. However, vonapanitase was associated with an approximately 30% reduced risk of fistula thrombosis. The majority of fistulas that thrombosed were abandoned (placebo, 95%; vonapanitase, 86%). Whereas vonapanitase was associated with only a 14% decreased risk for corrective procedures, vonapanitase fistulas requiring a procedure were less likely to be abandoned compared with placebo fistulas (22% vs 36%). This combination of less thrombosis and less abandonment after procedures explains how vonapanitase increased secondary patency. Primary patency was chosen as the primary end point as primary patency loss occurs frequently, is clinically meaningful, and is equally applicable to prehemodialysis and hemodialysis patients. However, secondary patency and use for hemodialysis are of greater relevance to patients, surgeons, and nephrologists. Inability to use the fistula means that patients on hemodialysis must dialyze with a catheter until a new permanent access becomes usable. This process typically requires a minimum of 3 months for fistulas 31 and probably much longer in most patients. 32 During this time, patients are at a heightened risk of serious infection, hospitalization, and death. 2, 33 Predialysis patients who lose secondary patency require another operation to create a permanent access, are more likely to initiate hemodialysis with a catheter, and suffer significantly higher mortality. 34 National goals for fistula use have been set at 66%, 3 and many centers have difficulty reaching this goal. For example, fistula use occurred in 44% of the placebo group in this study, very similar to the approximately 40% reported by the Dialysis Access Consortium fistula study, although these two studies defined use differently. 10 In contrast, fistula use was 64% in the vonapanitase group. An increase in use could translate into a decreased need for hemodialysis catheters and surgical procedures. A similarly designed but larger trial (n ¼ 600) of vonapanitase in radiocephalic fistulas (PATENCY-2 trial, NCT02414841) Fig 2. A, Kaplan-Meier estimates of fistula primary patency. Primary patency was lost at the time of the first occurrence of fistula thrombosis or procedure to restore or to maintain fistula patency. B, Kaplan-Meier estimates of fistula secondary patency. Secondary patency was lost at the time of fistula abandonment. is presently being conducted and is powered for the coprimary end points of secondary patency and use for hemodialysis.
There are no therapies available in the United States indicated to promote fistula patency and use for hemodialysis. Previous trials in fistulas evaluating systemic anticoagulation with aspirin, clopidogrel, and fish oil showed no improvement in fistula secondary patency or use for hemodialysis. 9, 10 Vonapanitase is applied once locally and has no systemic activity because it is inactivated by circulating antiproteases. 28 These characteristics minimize the risk of systemic toxicity. The most common adverse events in this and previous vonapanitase trials were related to the site of application and were not different between vonapanitase and placebo. [24] [25] [26] The one-time application of vonapanitase avoids issues with compliance, which is especially important in hemodialysis patients, who require many medications and struggle with adherence. 35 This trial has major strengths. It was a national, multicenter, randomized, double-blind, placebo-controlled study that allowed patients to be treated according to local standard of care. Standardized definitions for patency were also employed. 29 The trial also has limitations. This study included only patients undergoing creation of radiocephalic fistulas, and the results cannot be generalized to other types of fistulas or arteriovenous grafts. In addition, the follow-up time was 1 year, whereas fistula failure may occur during several years. However, patients completing the study with a patent fistula will be observed for up to an additional 2 years with further analysis. A larger sample size may have provided more power to detect a difference in primary patency.
CONCLUSIONS
A prospective, randomized, double-blind, placebocontrolled study was performed to determine whether topically applied vonapanitase would improve clinical outcomes in patients undergoing creation of a radiocephalic fistula. Vonapanitase did not significantly improve primary patency. However, vonapanitase was associated with increased fistula use for hemodialysis and fistula survival. These results need to be confirmed in a larger ongoing phase 3 clinical trial.
Additional material for this article may be found online at www.jvascsurg.org.
INVITED COMMENTARY
Thomas G. Lynch, MD, Washington, D.C.
On first reviewing this manuscript, I did have some concerns. The authors fail to achieve their primary goal; vonapanitase does not result in a significant increase in primary patency in patients receiving a radiocephalic arteriovenous fistula. Statistics in this study, however, may be misleading. The authors employ a hierarchical statistical model, which means that if the primary end point is not achieved, then the secondary and tertiary end points may only be considered descriptive.
The current study does suggest some potential advantages associated with vonapanitase, which support their plan for a further study with a larger population. Secondary patency at 12 months is significantly greater in the vonapanitase study group (P ¼ .048), as is the incidence of unassisted (P ¼ .035) and assisted and unassisted (P ¼ .006) fistula use. Maturation of the fistula is not affected by the study agent, and the need for interventional procedures appears comparable. Whereas the average outflow vein diameters at 6 weeks and 3 months are comparable, the outflow vein flow volume is increased with vonapanitase at 3 months (P ¼ .021). Analysis further suggests that vonapanitase could be associated with a decreased risk of fistula thrombosis and that fistulas undergoing intervention are less likely to be abandoned.
